What happened
On June 23, 2026, the board of CS Diagnostics Corp. (OTCQB: CSDX) determined that the company's previously issued financial statements for the fiscal years 2022, 2023, 2024, and 2025, along with any interim reports covering those periods, should no longer be relied upon. The decision follows a review of the company's accounting that was prompted by communications with the SEC's Division of Corporation Finance.
The $499.4 million intangible asset
The central problem is an intangible asset valued at approximately $499.4 million that was recorded in connection with a transaction on September 4, 2023. Management now believes that asset was improperly recognized and must be removed from the balance sheet entirely.
The company's preliminary view is that the transaction should have been treated under accounting rules for deals between entities under common control (ASC 805-50), not under a fair value acquisition model. Management is also reviewing whether other accounting standards apply, including those governing research and development costs, goodwill, and fair value measurement.
Removing the asset will require restating financials for one or more reporting periods. The company expects the restatement to materially reduce total assets and stockholders' equity, and it may also affect accumulated deficit, internal control conclusions, and other line items.
Auditor problems add to the mess
The company also disclosed that its former auditor, Olayinka Oyebola & Co., is subject to SEC and related regulatory restrictions. Any audit reports issued by that firm for historical periods can no longer be trusted, and any financial statements that relied on those audits are also unreliable.
CS Diagnostics has since hired Shah Teelani & Associates, a Dubai-based PCAOB-registered firm, as its new independent auditor. Shah Teelani will re-audit the affected periods and audit the fiscal year ended December 31, 2025. The company also retained KBF Advisory LLC as a technical accounting advisor to help sort through the accounting treatment of the intangible asset.
What comes next
The company says it has started a comprehensive review of its internal controls over financial reporting to find and fix the weaknesses that allowed the misstatement. It also committed to holding an annual shareholder meeting as soon as possible, where management plans to give a detailed update on the restatement process.
CS Diagnostics has not provided a firm timeline for completing the restated filings but said it intends to file them, along with its overdue 2025 annual report, as quickly as it can.
Why this matters for investors
A non-reliance determination covering four fiscal years is a serious red flag. It means every financial number the company has reported since 2022 is now in question. The removal of a $499.4 million asset from a company with a market capitalization of roughly $28 million will dramatically reshape the balance sheet. Investors should expect reported net worth to drop sharply once restated figures are published.
The company's stock trades on the OTCQB venture market, and it has already delayed its quarterly report for the period ended March 31, 2026. Until restated financials are filed, investors are operating without reliable baseline numbers.